Dimethylarginines ADMA and SDMA: the real water-soluble small toxins?

Semin Nephrol. 2014 Mar;34(2):97-105. doi: 10.1016/j.semnephrol.2014.02.003. Epub 2014 Feb 17.

Abstract

Uremia occurs if the kidney loses the ability to eliminate toxic compounds at a sufficient rate into the urine. In 1970, N-N, N-G- and N-G,N׳-G-dimethyl-arginine (asymmetric dimethylarginine [ADMA] and symmetric dimethylarginine) were isolated from human urine. It was anticipated that both substances might be important in the pathophysiology and for the diagnosis of various pathologic states. It took 22 years, however, before this idea materialized when it was found that ADMA, which is increased in hemodialysis patients, inhibits the synthesis of the endothelial-derived relaxing factor, identified as nitric oxide. ADMA correlates with traditional and nontraditional cardiovascular risk factors and is a strong predictor of cardiovascular events and death in both patients with chronic kidney disease and in the general population. It also seems to mediate adverse cardiovascular effects of drugs such as proton pump inhibitors. To date, we have no specific pharmacologic therapy at hand to neutralize the deleterious effects of ADMA, curbing the enthusiasm for this marker and mediator of cardiovascular disease.

Keywords: Chronic kidney disease (CKD); HDL; dialysis; mediator; risk factor.

Publication types

  • Review

MeSH terms

  • Arginine / analogs & derivatives*
  • Arginine / analysis
  • Arginine / physiology
  • Biomarkers / analysis
  • Cardiovascular Diseases / diagnosis
  • Cardiovascular Diseases / etiology
  • Humans
  • Kidney Diseases / diagnosis
  • Kidney Diseases / etiology
  • Water

Substances

  • Biomarkers
  • Water
  • symmetric dimethylarginine
  • N,N-dimethylarginine
  • Arginine